Frequently Asked Questions Is GLP-1 microdosing considered off-label use
Gastrointestinal symptomsparticularly nausea, vomiting, diarrhoea, and constipationare the most frequently reported adverse effects of GLP-1 receptor agonists, occurring in 2050% of patients depending on the specific agent and dose according to clinical trials and SmPC data
High-fat and high-sugar foods, for example, may trigger nausea or other digestive issues
The goal is finding the lowest dose that preserves appetite regulation while preventing further weight loss
Eligibility generally requires a BMI of 30 or higher , or a BMI of 27+ with a weight-related condition such as high blood pressure, high cholesterol, prediabetes, or type 2 diabetes, in line with standard GLP-1 prescribing guidelines
Novo says it's the only drugmaker to manufacture an FDA-approved Wegovy pill formulated with SNAC technology, which facilitates semaglutide absorption when administered orally